Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Extracellular vesicle mimics made from iPS cell-derived mesenchymal stem cells improve the treatment of metastatic prostate cancer

Fig. 3

Biodistribution of systemically infused rLuc-NVs in mice carrying subcutaneous prostate cancer. a The expression of GFP in NVs made from rLuc-GFP-transduced and non-transduced (NT) iPSC-MSCs was examined with flow cytometry. b The size distribution of NVs made from rLuc-transduced and NT iPSC-MSCs was determined with Nanosight nanoparticle tracking system. c The selective uptake of NT-NVs and rLuc-NVs by PC3 cells vs. SMCs (LOR) was measured as in Fig. 1. d In vitro bioluminescence activities of rLuc-NVs without or with pre-incubation with PC3 cells for 3 h were measured at 15 min after addition of rLuc substrate. RLU, relative luminescence units. e In vivo imaging of rLuc-NVs at 3, 12, 24, and 48 h after IP infusion of rLuc-NVs from ventral and dorsal side. f Absolute intensities of rLuc signals in Luc2+ tumor and non-tumor regions. g The percentages of tumor rLuc signals vs. total rLuc signals at corresponding time points (green dashed line) and vs. total rLuc signals at 3 h (blue solid line). N = 4 in all assays; ns, not significant

Back to article page